SHARP is mislocalized in myotonic dystrophy [228], while, in acute myeloid leukemia (AML), it has been proposed to have an altered function as consequence of its interaction with the oncofusion protein AML1/ETO deregulating the Notch signaling pathway [173,174]. Here, SPEN is linked to acute myeloid leukemia.